Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Biosciences International Sàrl
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Subjects who have disease progression after treatment with available therapies that are known to confer clinical benefit, or who are intolerant to treatment, or who refuse standard treatment. There is no limit to the number of prior treatment regimens.
Part 1: Subjects with advanced or metastatic solid tumors.
Part 2: Subjects with advanced or metastatic adenocarcinoma of the endometrium, ovarian cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer.
Presence of measureable disease based on RECIST v1.1.
Eastern Cooperative Oncology Group performance status 0 or 1.
You may not be if
Laboratory and medical history parameters not within the protocol-defined range.
Receipt of anticancer medications or investigational drugs within the protocol-defined intervals before the first administration of study drug.
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy (including prior immunotherapy) and/or complications from prior surgical intervention before starting therapy.
Receipt of a live vaccine within 30 days of planned start of study drug.
Active autoimmune disease that required systemic treatment in the past.
Clareo Health | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
